peak WW sales of 812B+ for the hep C business. We also expect solid growth for the HIV franchise supported by the continued launch of Stribild and Complera, both once-daily, single-tablet regimens. Additionally, we expect oncology to begin to contribute to revenue growth with approval of idelalisib in

nces Inc. HCV Still Near and LT Focus Upside Sovaldi (4611M vs cons) drove a $0.57 EPS beat: Sovaldi (4611M), Truvada (+$18M), Viread (+$24M) and Complera (+$22M) drove the $685M rev beat vs cons. Better gross margins (89% vs MSe 86%) and a lower tax rate (14.6% with a 1 qtr 3.6% catch-up) represente